Nektar Therapeutics (MEX:NKTR) Cyclically Adjusted Revenue per Share: MXN563.45 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NKTR Nektar Therapeutics MEX:NKTR
50 GF Score
Price MXN1,584.15
GF Value MXN120.43
! 4 Warning Signs
View Full Analysis

What is Nektar Therapeutics Cyclically Adjusted Revenue per Share?

Nektar Therapeutics MEX:NKTR 50 Cyclically Adjusted Revenue per Share is MXN563.45 as of Jun. 2026. GuruFocus rates MEX:NKTR with a GF Score™ of 50/100 and a GF Value™ of MXN120.43. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Nektar Therapeutics's adjusted revenue per share for the three months ended in Jun. 2026 was MXN5.348. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN563.45 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Nektar Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -6.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -1.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Nektar Therapeutics was 16.80% per year. The lowest was -5.80% per year. And the median was 0.50% per year.

As of today (2026-08-20), Nektar Therapeutics's current stock price is MXN1584.15. Nektar Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN563.45. Nektar Therapeutics's Cyclically Adjusted PS Ratio of today is 2.81.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nektar Therapeutics was 81.75. The lowest was 0.23. And the median was 8.32.


Nektar Therapeutics  (MEX:NKTR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Nektar Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1584.15/563.45
=2.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nektar Therapeutics was 81.75. The lowest was 0.23. And the median was 8.32.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Nektar Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Nektar Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Nektar Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Cyclically Adjusted Revenue per Share Chart

Nektar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 664.15 4,140.46 2,655.01 539.03 618.54

Nektar Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 170.04 247.64 618.54 458.67 563.45

MEX:NKTR vs PHVS, MLYS, NRIX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Nektar Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Cyclically Adjusted PS Ratio falls into.


MEX:NKTR
50GF Score
Nektar Therapeutics MEX:NKTR
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nektar Therapeutics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.348/333.9520*333.9520
=5.348

Current CPI (Jun. 2026) = 333.9520.

Nektar Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 76.868 241.428 106.327
201612 77.657 241.432 107.416
201703 45.451 243.801 62.258
201706 60.368 244.955 82.301
201709 255.957 246.819 346.316
201712 177.598 246.524 240.582
201803 64.395 249.554 86.173
201806 1,758.668 251.989 2,330.700
201809 45.104 252.439 59.668
201812 64.584 251.233 85.848
201903 47.231 254.202 62.049
201906 38.486 256.143 50.177
201909 49.331 256.759 64.162
201912 54.384 256.974 70.675
202003 100.392 258.115 129.888
202006 94.843 257.797 122.860
202009 55.571 260.280 71.300
202012 38.954 260.474 49.943
202103 39.978 264.877 50.404
202106 46.300 271.696 56.909
202109 41.749 274.310 50.826
202112 41.602 278.802 49.831
202203 39.890 287.504 46.334
202206 34.871 296.311 39.301
202209 37.990 296.808 42.744
202212 34.212 296.797 38.495
202303 30.911 301.836 34.200
202306 27.794 305.109 30.421
202309 33.131 307.789 35.947
202312 31.831 306.746 34.654
202403 27.661 312.332 29.576
202406 30.912 314.175 32.858
202409 34.051 315.301 36.065
202412 43.508 315.605 46.037
202503 15.217 319.799 15.890
202506 14.937 322.561 15.464
202509 11.415 324.800 11.737
202512 19.309 324.054 19.899
202603 7.918 330.213 8.008
202606 5.348 333.952 5.348

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN563.45 mean?
Nektar Therapeutics (MEX:NKTR) has a Cyclically Adjusted Revenue per Share of MXN563.45 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nektar Therapeutics and its competitors.
Is Nektar Therapeutics' Cyclically Adjusted Revenue per Share too high?
Nektar Therapeutics' current Cyclically Adjusted Revenue per Share is MXN563.45. Overall, Nektar Therapeutics has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Cyclically Adjusted Revenue per Share compare to PHVS and MLYS?
Nektar Therapeutics' Cyclically Adjusted Revenue per Share of MXN563.45 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nektar Therapeutics and its competitors. Nektar Therapeutics's current Cyclically Adjusted Revenue per Share is MXN563.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Nektar Therapeutics (MEX:NKTR) has a current Cyclically Adjusted Revenue per Share of MXN563.45. The stock's GF Value™ is MXN120.43, compared to a current price of MXN1,584.15 — trading 1215.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN563.45. Nektar Therapeutics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Nektar Therapeutics (MEX:NKTR), the current Cyclically Adjusted Revenue per Share is MXN563.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (MEX:NKTR) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of MXN1,584.15 is trading 1215.4% above its estimated GF Value™ of MXN120.43.

Key valuation signals for MEX:NKTR:

  • Cyclically Adjusted Revenue per Share: MXN563.45
  • GF Value™: MXN120.43 vs. price of MXN1,584.15 (1215.4% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the MEX:NKTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nektar Therapeutics Business Description

Other Exchanges NKTR:USA0UNL:UKITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
50GF Score

Get the complete analysis for MEX:NKTR

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,584.15
Price
MXN120.43
GF Value